The tool allows developers to enhance their games' accessibility.
Ubisoft released Chroma, a simulation tool that allows developers to make their games more accessible for people affected by colorblindness.
Chroma applies a filter over the game screen to show how colorblind people see the world. The filter runs without impacting performance and helps developers make adjustments to improve the accessibility of their games. Chroma is based on the Color Oracle algorithm and supports dual or single screens, also including a customizable overlay and hotkey support.
David Tisserand, Director of Accessibility, says: "Chroma has proven to be a highly efficient tool for us at Ubisoft. It has allowed us to assess the accessibility of our games for colorblind players much faster and more comprehensively than ever before," he explains. "Because we believe accessibility is a journey, not a race, we're thrilled to share Chroma with the entire industry. We invite everyone to benefit from it, provide feedback, and contribute to its future development."
"Chroma was created with a clear purpose – making color blindness accessibility a natural part of the creative and testing process," points out Jawad Shakil, QC Product Manager. "The team faced and overcame significant challenges while building it, but through close collaboration with accessibility experts and by refining the tool based on feedback, they created a solution that eliminated lag and inaccuracies, making accessibility testing efficient and smooth."
The tool has been in development since 2021, with initial work led by Ubisoft's Quality Control team in India. At the time, the team worked on a tool that provided feedback in real time and let developers interact with the game while simulating colorblindness.
Chroma is an open-source tool and is available here.
Also, don't forget to join our 80 Level Talent platform and our new Discord server, follow us on Instagram, Twitter, LinkedIn, Telegram, TikTok, and Threads, where we share breakdowns, the latest news, awesome artworks, and more.